ABX.TO (ABX.TO)
Quantitative Summary
DeterministicFinancial health metrics are strong: Piotroski 9/9, Altman Z 4.5 (above 3.0 safe zone threshold).
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe company exhibits exceptional fundamental quality, characterized by a robust ROIC-WACC spread of +4.4% that signals strong value creation relative to the cost of capital. This economic moat is primarily driven by an impressive net margin expansion to 29.4%, which more than offsets modest asset turnover at 0.33x and moderate leverage via an equity multiplier of 1.44x, resulting in a DuPont-decomposed ROE of 13.9%. Financial integrity metrics further validate this profile; the perfect Piotroski F-Score of 9/9 indicates robust financial health across nine dimensions, while the Altman Z-Score of 4.5 and Beneish M-Score of -3.01 suggest a very low probability of bankruptcy and minimal earnings manipulation risk respectively.
Valuation metrics present a compelling divergence between current pricing and intrinsic value estimates. Trading at a P/E multiple of 13.4x, the stock appears significantly discounted relative to its trajectory given revenue growth accelerating at 31.2% YoY and gross margins holding steady above 50%. A DCF analysis anchors fair value at $75, implying that current market pricing may be conservative if the underlying assumptions regarding future cash flow generation hold true. This setup suggests the market has not yet fully priced in the sustainability of such high growth rates combined with superior profitability ratios.
While specific sector benchmarks and historical multiple comparisons are unavailable to contextualize the 13.4x P/E further, the convergence of aggressive top-line expansion, expansive margins, and pristine financial scores creates a favorable risk-reward asymmetry absent typical distress signals or earnings opacity concerns inherent in many high-growth peers.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 8.6% | 10.6% | 12.6% |
|---|---|---|---|
| 2% | $90 | $68 | $54 |
| 3% | $104 | $75 | $58 |
| 4% | $123 | $84 | $64 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=10.7%, terminal growth 3%. Fair value $75 (+0.0%). Not investment advice.
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
✅ Conservative payout — room for dividend increases.
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
ABX.TO Capital Efficiency
How efficiently does ABX.TO convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
ABX.TO converts 35% of its EBITDA into free cash flow, a moderate conversion rate — significant EBITDA is consumed by capital expenditures, working capital changes, or interest payments. The 65% reinvestment rate signals aggressive capacity expansion. The positive ROIC-WACC spread of 4.4% confirms that reinvested capital creates shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Compare ABX.TO to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.